Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Buck

Showing results (321-330 of 400) with videos related to

Pageof 40
Sort By:
JAMA Network Open|April 21, 2021
Accuracy of 18-F Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Imaging in Primary Staging of Squamous Cell Carcinoma of the Oral CavityChristian Linz, Roman C Brands, Theresia Herterich, et al.
Molecular Imaging and Biology|January 22, 2008
Performance of integrated FDG-PET/CT for differentiating benign and malignant lung lesions--results from a large prospective clinical trialSandra Pauls, Andreas K Buck, Gisela Halter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2012
[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent mannerNicolas Graf, Ken Herrmann, Barbara Numberger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 4, 2018
Prognostic value of [<sup>18</sup>F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantationAntje Stolzenburg, Katharina Lückerath, Samuel Samnick, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2015
Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapyKen Herrmann, Christina Bluemel, Martina Weineisen, et al.
Endocrine|May 4, 2016
Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomographyRudolf A Werner, Matthias Kroiss, Masatoyo Nakajo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2010
[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft modelBernd J Krause, Michael Souvatzoglou, Ken Herrmann, et al.
Pediatrics|June 5, 2001
A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonatesJ S Garland, C P Alex, C D Mueller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphomaKen Herrmann, Hinrich A Wieder, Andreas K Buck, et al.
Pageof 40

Showing results (321-330 of 400) with videos related to

Sort By:
Pageof 40
JAMA Network Open|April 21, 2021
Accuracy of 18-F Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Imaging in Primary Staging of Squamous Cell Carcinoma of the Oral CavityChristian Linz, Roman C Brands, Theresia Herterich, et al.
Molecular Imaging and Biology|January 22, 2008
Performance of integrated FDG-PET/CT for differentiating benign and malignant lung lesions--results from a large prospective clinical trialSandra Pauls, Andreas K Buck, Gisela Halter, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 12, 2012
[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent mannerNicolas Graf, Ken Herrmann, Barbara Numberger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 4, 2018
Prognostic value of [<sup>18</sup>F]FDG-PET/CT in multiple myeloma patients before and after allogeneic hematopoietic cell transplantationAntje Stolzenburg, Katharina Lückerath, Samuel Samnick, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 18, 2015
Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapyKen Herrmann, Christina Bluemel, Martina Weineisen, et al.
Endocrine|May 4, 2016
Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomographyRudolf A Werner, Matthias Kroiss, Masatoyo Nakajo, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Improved Primary Staging of Marginal-Zone Lymphoma by Addition of CXCR4-Directed PET/CTJohannes Duell, Franziska Krummenast, Andreas Schirbel, et al.
European Journal of Nuclear Medicine and Molecular Imaging|June 1, 2010
[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft modelBernd J Krause, Michael Souvatzoglou, Ken Herrmann, et al.
Pediatrics|June 5, 2001
A randomized trial comparing povidone-iodine to a chlorhexidine gluconate-impregnated dressing for prevention of central venous catheter infections in neonatesJ S Garland, C P Alex, C D Mueller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2007
Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphomaKen Herrmann, Hinrich A Wieder, Andreas K Buck, et al.
Pageof 40